 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- || admilparant (BMS-986278) / BMS
Clinical, P2 data, Journal: Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (Pubmed Central) - Oct 11, 2024
P2
In this first phase 2 study to evaluate antifibrotic treatment in parallel IPF and PPF cohorts, 60-mg admilparant slowed lung function decline and was safe and well tolerated, supporting further evaluation in phase 3 trials. Clinical trial registration available at www.
- deupirfenidone (LYT-100) / PureTech
BAYESIAN APPROACH FOR ELEVATE IPF: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE EFFICACY, SAFETY, AND DOSE RESPONSE OF DEUPIRFENIDONE (LYT-100) IN IPF (Convention Center Exhibit Hall: Rapid Fire Area 2B) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6789;
Clinical trial registration available at www. There is precedent for leveraging Bayesian methodology in IPF studies (i.e., phase 2 programs for BI 1015550 and BMS-986278) to minimize the number of patients exposed to placebo while still generating data sufficient for decision making in drug development...The study will evaluate approximately 240 treatment-na
- || Review, Journal: Evidence from recent clinical trials in fibrotic interstitial lung diseases. (Pubmed Central) - Aug 8, 2024
There is precedent for leveraging Bayesian methodology in IPF studies (i.e., phase 2 programs for BI 1015550 and BMS-986278) to minimize the number of patients exposed to placebo while still generating data sufficient for decision making in drug development...The study will evaluate approximately 240 treatment-na Despite recent frustrating negative results, there is a growing portfolio of candidate drugs developed in both IPF and PPF.
- admilparant (BMS-986278) / BMS
Effects of lysophosphatidic acid receptor 1 (LPA1) antagonism on biomarkers in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): data from a randomized phase 2 trial with BMS-986278 (A1) - May 31, 2024 - Abstract #ERS2024ERS_2757;
P2
Despite recent frustrating negative results, there is a growing portfolio of candidate drugs developed in both IPF and PPF. Treatment with BMS-986278 over 26 weeks significantly improved biomarkers of epithelial injury and fibrosis in patients with IPF, and biomarkers of inflammation and fibrosis in patients with PPF, consistent with effective antagonism of the LPA1 pathway.
- || admilparant (BMS-986278) / BMS
New P1 trial: Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (clinicaltrials.gov) - May 22, 2024
P1, N=48, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | BMS-986278 / BMS
Journal: Peroxygenase-Catalyzed Allylic Oxidation Unlocks Telescoped Synthesis of (1S,3R)-3-Hydroxycyclohexanecarbonitrile. (Pubmed Central) - Mar 7, 2024
Inspired by the discovery route toward the LPA1-antagonist BMS-986278, access to the API building block (1S,3R)-3-hydroxycyclohexanecarbonitrile was envisaged using an ene reductase (ER) and alcohol dehydrogenase (ADH) to set both stereocenters...After screening of enzyme panels, the final product was obtained at titers of 85% with 97% ee and 99% de, with a substrate loading of 50 mM, the ER being the limiting step. This synthetic approach provides the first example of a three-step, one-pot UPO-ER-ADH cascade and highlights the potential for UPOs to catalyze diverse enantioselective allylic hydroxylations and oxidations that are otherwise difficult to achieve.
- admilparant (BMS-986278) / BMS
Effect of BMS-986278, An Oral LPA1 Antagonist, on Time to Disease Progression in Patients With Pulmonary Fibrosis: A Post Hoc Analysis of Data From a Phase 2 Randomized Trial (San Diego Convention Center, Ballroom 20A (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_7132;
P2
This synthetic approach provides the first example of a three-step, one-pot UPO-ER-ADH cascade and highlights the potential for UPOs to catalyze diverse enantioselective allylic hydroxylations and oxidations that are otherwise difficult to achieve. Consistent with the primary results, this analysis showed that BMS-986278 60 mg delayed time to disease progression over 26 weeks compared with placebo in patients with IPF.
- || admilparant (BMS-986278) / BMS
Trial completion: A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants (clinicaltrials.gov) - Jan 23, 2024
P1, N=37, Completed, Sponsor: Bristol-Myers Squibb
Consistent with the primary results, this analysis showed that BMS-986278 60 mg delayed time to disease progression over 26 weeks compared with placebo in patients with IPF. Recruiting --> Completed
- |||||| admilparant (BMS-986278) / BMS
Enrollment open: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis (clinicaltrials.gov) - Nov 14, 2023
P3, N=1092, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Not yet recruiting --> Recruiting
- || admilparant (BMS-986278) / BMS
Trial completion: A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants (clinicaltrials.gov) - Oct 30, 2023
P1, N=47, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| admilparant (BMS-986278) / BMS
Trial completion, Enrollment change: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Oct 24, 2023
P2, N=399, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Active, not recruiting --> Completed | N=278 --> 399
- || admilparant (BMS-986278) / BMS
Enrollment open: A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants (clinicaltrials.gov) - Sep 30, 2023
P1, N=36, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=278 --> 399 Not yet recruiting --> Recruiting
- |||||| admilparant (BMS-986278) / BMS
Enrollment open: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Sep 26, 2023
P3, N=1185, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || admilparant (BMS-986278) / BMS
Enrollment open: A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants (clinicaltrials.gov) - Sep 22, 2023
P1, N=48, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || admilparant (BMS-986278) / BMS
Trial completion: A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants (clinicaltrials.gov) - Sep 18, 2023
P1, N=24, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||||||||| admilparant (BMS-986278) / BMS
New P3 trial: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis (clinicaltrials.gov) - Sep 6, 2023
P3, N=1092, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| admilparant (BMS-986278) / BMS
Trial completion: A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2) (clinicaltrials.gov) - Aug 24, 2023
P1, N=61, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Completed Recruiting --> Completed
- |||||||||| admilparant (BMS-986278) / BMS
New P3 trial: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Aug 22, 2023
P3, N=1185, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || admilparant (BMS-986278) / BMS
New P1 trial: A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants (clinicaltrials.gov) - Aug 14, 2023
P1, N=36, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- BMS-986278 / BMS
RCT Abstract - BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomized controlled trial (Silver) - Jul 20, 2023 - Abstract #ERS2023ERS_5796;
Recruiting --> Completed Cell and molecular biology; Transplantation; General respiratory patient care; Pulmonary function testing
- || admilparant (BMS-986278) / BMS
New P1 trial: A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants (clinicaltrials.gov) - Jul 6, 2023
P1, N=48, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || admilparant (BMS-986278) / BMS
New P1 trial: A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants (clinicaltrials.gov) - Apr 10, 2023
P1, N=24, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- BMS-986278 / BMS
BMS-986278, an Oral Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist, for Patients With Idiopathic Pulmonary Fibrosis: Results From a Phase 2 Randomized Trial (Walter E. Washington Convention Center, Ballroom B (Level 3)) - Mar 25, 2023 - Abstract #ATS2023ATS_3908;
P2
BMS-986278 was safe and well tolerated with rates of gastrointestinal AEs and treatment discontinuation comparable to placebo. These findings support continued development of BMS-986278 for pulmonary fibrosis.
- ||| admilparant (BMS-986278) / BMS
Enrollment open: A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2) (clinicaltrials.gov) - Feb 10, 2023
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
These findings support continued development of BMS-986278 for pulmonary fibrosis. Not yet recruiting --> Recruiting
- ||| admilparant (BMS-986278) / BMS
New P1 trial: A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2) (clinicaltrials.gov) - Jan 13, 2023
P1, N=60, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| admilparant (BMS-986278) / BMS
Enrollment closed, Trial completion date: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Sep 23, 2022
P2, N=373, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Sep 2023
- BMS-986278 / BMS
First-in-human evaluation of 18F-BMS-986327 as a novel PET tracer to assess lysophosphatidic acid receptor 1 (LPA1) target engagement in the lung (TP-26 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3451;
P1, P2
Initial data support 18F-BMS-986327 administration at doses up to 1.1 mCi, or up to 3.5 mCi with a fatty meal. Together with low TRT variability, these results support the further evaluation of 18BMS-986327 in a substudy of NCT04308681 to assess BMS-986278 target engagement in patients with lung fibrosis.
- || admilparant (BMS-986278) / BMS
Enrollment change: A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole) (clinicaltrials.gov) - May 10, 2022
P1, N=24, Completed, Sponsor: Bristol-Myers Squibb
Together with low TRT variability, these results support the further evaluation of 18BMS-986327 in a substudy of NCT04308681 to assess BMS-986278 target engagement in patients with lung fibrosis. N=104 --> 24
- || BMS-986278 / BMS
Clinical, P2 data, Journal: Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). (Pubmed Central) - Mar 24, 2022
P2
Results will be reported in a peer-reviewed publication. NCT04308681.
- ||| admilparant (BMS-986278) / BMS
Trial completion, Enrollment change: A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole) (clinicaltrials.gov) - Mar 22, 2022
P1, N=104, Completed, Sponsor: Bristol-Myers Squibb
NCT04308681. Not yet recruiting --> Completed | N=24 --> 104
- | BMS-986234 / BMS, BMS-986278 / BMS, BMS-986020 / BMS
Preclinical, Journal: Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA) antagonists. (Pubmed Central) - Mar 11, 2022
Mixed effects on plasma bile acids in both rat and monkey has made this biomarker not a useful predictor of the hepatobiliary toxicity. In conclusion, the nonclinical data indicate the hepatobiliary toxicity observed clinically and in monkeys administered BMS-986020 is compound specific and not mediated via antagonism of LPA.
- | BMS-986234 / BMS, BMS-986278 / BMS, BMS-986020 / BMS
Journal: Mechanism of hepatobiliary toxicity of the LPA antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278. (Pubmed Central) - Mar 11, 2022
The data indicate that this toxicity was unrelated to LPA antagonism since the mechanisms that likely influenced the adverse clinical outcome of BMS-986020 were not observed with equipotent LPA antagonists BMS-986234 and BMS-986278. This conclusion is consistent with the lack of hepatobiliary toxicity in nonclinical and clinical safety studies with BMS-986278.
- || admilparant (BMS-986278) / BMS
Trial completion, Trial completion date, Trial primary completion date: Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants (clinicaltrials.gov) - Mar 11, 2022
P1, N=9, Completed, Sponsor: Bristol-Myers Squibb
This conclusion is consistent with the lack of hepatobiliary toxicity in nonclinical and clinical safety studies with BMS-986278. Not yet recruiting --> Completed | Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Apr 2021
- || admilparant (BMS-986278) / BMS
Trial primary completion date: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Jan 24, 2022
P2, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Completed | Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Apr 2021 Trial primary completion date: May 2023 --> Aug 2022
- || HZN-825 / Horizon Therapeutics, BMS-986278 / BMS, BMS-986020 / BMS
Review, Journal: The development of modulators for lysophosphatidic acid receptors: A comprehensive review. (Pubmed Central) - Jan 15, 2022
While no drugs targeting LPARs have been approved by the FDA thus far, at least three antagonists have entered phase Ⅱ clinical trials for idiopathic pulmonary fibrosis (BMS-986020 and BMS-986278) and systemic sclerosis (SAR100842), and one radioligand (BMT-136088/F-BMS-986327) has entered phase Ⅰ clinical trials for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis. This article provides an extensive review on the current status of ligand development targeting LPA receptors to modulate LPA signaling and their therapeutic potential in various diseases.
- | BMS-986278 / BMS
Journal: Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. (Pubmed Central) - Dec 16, 2021
P2
The detailed in vitro and in vivo preclinical pharmacology profiles of 33, as well as its pharmacokinetics/metabolism profile, are described. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, 33 was advanced into clinical trials, including an ongoing Phase 2 clinical trial in patients with lung fibrosis (NCT04308681).
- || admilparant (BMS-986278) / BMS
Trial primary completion date: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Apr 22, 2021
P2, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, 33 was advanced into clinical trials, including an ongoing Phase 2 clinical trial in patients with lung fibrosis (NCT04308681). Trial primary completion date: Nov 2023 --> May 2023
- || admilparant (BMS-986278) / BMS
New P1 trial: Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants (clinicaltrials.gov) - Sep 27, 2020
P1, N=9, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- BMS-986278 / BMS
[VIRTUAL] Discovery of LPA receptor antagonist clinical candidate BMS-986278 for the treatment of idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation (On Demand Oral) - Aug 20, 2020 - Abstract #ACSFall2020ACS-Fall_5587;
In contrast to BMS-986020, BMS-986278 has negligible activity at bile acid and other clinically relevant drug transporters such as BSEP and MDR3 (IC50 >100 µM). BMS-986278 is thus a novel, promising LPA1 receptor antagonist for the treatment of IPF and other fibrotic diseases.
- BMS-986278 / BMS
[VIRTUAL] Discovery of LPA receptor antagonist clinical candidate BMS-986278 for the treatment of idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation (Broadcast) - Aug 20, 2020 - Abstract #ACSFall2020ACS-Fall_1037;
In contrast to BMS-986020, BMS-986278 has negligible activity at bile acid and other clinically relevant drug transporters such as BSEP and MDR3 (IC50 >100 µM). BMS-986278 is thus a novel, promising LPA1 receptor antagonist for the treatment of IPF and other fibrotic diseases.
- |||| admilparant (BMS-986278) / BMS
Enrollment open: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Aug 7, 2020
P2, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
BMS-986278 is thus a novel, promising LPA1 receptor antagonist for the treatment of IPF and other fibrotic diseases. Not yet recruiting --> Recruiting
- rifampicin / Generic mfg., BMS-986278 / BMS
[VIRTUAL] Effect of rifampin, a potent organic-anion-transporting polypeptide inhibitor (OATPi), on the PK of BMS-986278, a lysophosphatidic acid receptor (LPA1) antagonist (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_1192;
CONCLUSIONS BMS-986278+rif and BMS-986278 alone were generally well tolerated; increases in exposure up to 3x of BMS-986278 were observed with co-administration of rif. Concomitant OATPi medications anticipated to increase BMS-986278 exposure <2x are permitted in future studies.
- || admilparant (BMS-986278) / BMS
New P1 trial: A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole) (clinicaltrials.gov) - Jul 12, 2020
P1, N=24, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- BMS-986278 / BMS
[VIRTUAL] BMS-986278, A Lysophosphatidic Acid 1 (LPA 1 ) Receptor Antagonist, in Healthy Participants: A Single/Multiple Ascending Dose (SAD/MAD) and Japanese MAD (JMAD) Phase 1 Study (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_2835;
Dose-proportional PK was observed, and dosing is supported with/without food. Study of BMS‑986278 in IPF is warranted.
- || admilparant (BMS-986278) / BMS
Trial completion date, Trial primary completion date: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Jun 25, 2020
P2, N=360, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Study of BMS‑986278 in IPF is warranted. Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jan 2023 --> Nov 2023
- || admilparant (BMS-986278) / BMS
Trial completion date, Trial primary completion date: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Jun 17, 2020
P2, N=360, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jan 2023 --> Nov 2023 Trial completion date: May 2022 --> Jul 2023 | Trial primary completion date: May 2022 --> Jan 2023
- ||||| admilparant (BMS-986278) / BMS
New P2 trial: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (clinicaltrials.gov) - Mar 16, 2020
P2, N=360, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- BMS-986278 / BMS
BMS-986278, A Lysophosphatidic Acid 1 (LPA1) Receptor Antagonist, in Healthy Participants: A Single/Multiple Ascending Dose (SAD/MAD) and Japanese MAD (JMAD) Phase 1 Study (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area D) - Mar 15, 2020 - Abstract #ATS2020ATS_5167;
Dose-proportional PK was observed, and dosing is supported with/without food. Study of BMS‑986278 in IPF is warranted.
- BMS-986278 / BMS
Discovery of LPA1 receptor antagonist clinical candidate BMS-986278 for the treatment of idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation (Grand Ballroom B, Pennsylvania Convention Center) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_15927;
In contrast to BMS-986020, BMS-986278 has negligible activity at bile acid and other clinically relevant drug transporters such as BSEP and MDR3 (IC50 >100 mM). BMS-986278 is thus a novel, promising LPA1 receptor antagonist for the treatment of IPF and other fibrotic diseases.
- || admilparant (BMS-986278) / BMS
Trial completion: A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants (clinicaltrials.gov) - Nov 27, 2019
P1, N=22, Completed, Sponsor: Bristol-Myers Squibb
BMS-986278 is thus a novel, promising LPA1 receptor antagonist for the treatment of IPF and other fibrotic diseases. Recruiting --> Completed